Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 17/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 10/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.35 |
| ▸ | PER2 | O15055 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13695429 | 0.78 | PTGER2 (0.36) | PTGER2PTGER3CDK2 | |
| SCHEMBL13385596 | 0.77 | PTGER2 (0.56) | PTGER2PTGER3PTGER4PTGDRPTGER1 | |
| SCHEMBL13626386 | 0.75 | PTGER2 (0.59) | PTGER2PTGER3CCNA2CDK2CCNA1 | |
| SCHEMBL22352609 | 0.75 | PTGER2 (0.59) | PTGER2PTGER3CCNA2CDK2CCNA1 | |
| SCHEMBL13626389 | 0.74 | CCNA2 (0.45) | PTGER2PTGER3CCNA2CDK2CCNA1 | |
| SCHEMBL13626387 | 0.72 | DHODH (0.47) | PTGER2PTGER3CCNA2CDK2CCNA1 | |
| SCHEMBL10021107 | 0.72 | PTGER2 (0.41) | PTGER2PTGER3 | |
| SCHEMBL9892974 | 0.72 | L3MBTL1 (0.53) | CCNA2CDK2CCNA1 | |
| SCHEMBL13232169 | 0.72 | PTGER2 (0.41) | PTGER2PTGER3 | |
| SCHEMBL13626391 | 0.71 | ABL1 (0.39) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286787-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | PTGER2 3210/4885PTGER3 2745/4885CCNA2 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.